> top > docs > PubMed:32586394 > annotations

PubMed:32586394 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 98-105 Body_part denotes Heparin http://purl.org/sig/ont/fma/fma82839
T2 355-362 Body_part denotes Heparin http://purl.org/sig/ont/fma/fma82839
T3 2068-2076 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851
T4 2283-2290 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T5 2729-2741 Body_part denotes heart valves http://purl.org/sig/ont/fma/fma7110
T6 2729-2734 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T7 2868-2875 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T8 3768-3772 Body_part denotes Body http://purl.org/sig/ont/fma/fma256135
T9 5472-5478 Body_part denotes Plasma http://purl.org/sig/ont/fma/fma62970
T10 5503-5511 Body_part denotes Platelet http://purl.org/sig/ont/fma/fma62851
T11 5520-5530 Body_part denotes Lymphocyte http://purl.org/sig/ont/fma/fma62863
T12 5531-5541 Body_part denotes Neutrophil http://purl.org/sig/ont/fma/fma62860
T13 5554-5560 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T14 6009-6020 Body_part denotes haemoglobin http://purl.org/sig/ont/fma/fma62293
T15 6080-6095 Body_part denotes red blood cells http://purl.org/sig/ont/fma/fma62845
T16 6090-6095 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T17 6231-6234 Body_part denotes eye http://purl.org/sig/ont/fma/fma54448
T18 6342-6353 Body_part denotes compartment http://purl.org/sig/ont/fma/fma76577
T19 8933-8940 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 2729-2734 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T2 6084-6089 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T3 6217-6223 Body_part denotes corpus http://purl.obolibrary.org/obo/UBERON_3000645
T4 6231-6234 Body_part denotes eye http://purl.obolibrary.org/obo/UBERON_0000970

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 151-159 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 160-169 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T3 174-186 Disease denotes coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T4 234-242 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 243-245 Disease denotes HD http://purl.obolibrary.org/obo/MONDO_0007739
T6 515-522 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 731-758 Disease denotes Acute Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0004781
T8 737-758 Disease denotes Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0005068
T9 813-835 Disease denotes venous thromboembolism http://purl.obolibrary.org/obo/MONDO_0005399
T10 1390-1400 Disease denotes Infectious http://purl.obolibrary.org/obo/MONDO_0005550
T11 1421-1440 Disease denotes Respiratory Disease http://purl.obolibrary.org/obo/MONDO_0005087
T12 1521-1529 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T13 1599-1608 Disease denotes pneumonia http://purl.obolibrary.org/obo/MONDO_0005249
T14 1791-1803 Disease denotes Coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T15 1949-1961 Disease denotes Coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T16 2050-2066 Disease denotes Thrombocytopenia http://purl.obolibrary.org/obo/MONDO_0002049
T17 2100-2112 Disease denotes Coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T18 2188-2191 Disease denotes CKD http://purl.obolibrary.org/obo/MONDO_0005300
T19 2238-2254 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T21 2283-2315 Disease denotes heparin induced thrombocytopenia http://purl.obolibrary.org/obo/MONDO_0018048
T22 2299-2315 Disease denotes thrombocytopenia http://purl.obolibrary.org/obo/MONDO_0002049
T23 2446-2452 Disease denotes stroke http://purl.obolibrary.org/obo/MONDO_0005098|http://purl.obolibrary.org/obo/MONDO_0011057
T25 2454-2466 Disease denotes peptic ulcer http://purl.obolibrary.org/obo/MONDO_0004247
T26 2461-2466 Disease denotes ulcer http://purl.obolibrary.org/obo/MONDO_0043839
T27 2478-2484 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T28 2577-2604 Disease denotes arteriovenous malformations http://purl.obolibrary.org/obo/MONDO_0001256
T29 2673-2692 Disease denotes atrial fibrillation http://purl.obolibrary.org/obo/MONDO_0004981
T30 2694-2716 Disease denotes venous thromboembolism http://purl.obolibrary.org/obo/MONDO_0005399
T31 4391-4418 Disease denotes Acute Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0004781
T32 4397-4418 Disease denotes Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0005068
T33 4473-4495 Disease denotes venous thromboembolism http://purl.obolibrary.org/obo/MONDO_0005399
T34 5016-5043 Disease denotes Acute Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0004781
T35 5022-5043 Disease denotes Myocardial Infarction http://purl.obolibrary.org/obo/MONDO_0005068
T36 5098-5120 Disease denotes venous thromboembolism http://purl.obolibrary.org/obo/MONDO_0005399
T37 6342-6362 Disease denotes compartment syndrome http://purl.obolibrary.org/obo/MONDO_0004001
T38 7057-7066 Disease denotes Epistaxis http://purl.obolibrary.org/obo/MONDO_0005305

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 248-249 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 272-273 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 290-300 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T4 581-582 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 766-777 http://purl.obolibrary.org/obo/BFO_0000030 denotes Objectively
T6 801-809 http://purl.obolibrary.org/obo/UBERON_0001637 denotes arterial
T7 801-809 http://www.ebi.ac.uk/efo/EFO_0000814 denotes arterial
T8 837-841 http://purl.obolibrary.org/obo/CLO_0009316 denotes TE]4
T9 880-886 http://purl.obolibrary.org/obo/UBERON_0001005 denotes Airway
T10 1215-1220 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T11 1242-1246 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T12 1248-1251 http://purl.obolibrary.org/obo/CLO_0053733 denotes 1:1
T13 1491-1493 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T14 1571-1578 http://purl.obolibrary.org/obo/UBERON_0001005 denotes airways
T15 1975-1978 http://purl.obolibrary.org/obo/CLO_0053799 denotes 4 5
T16 2023-2025 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T17 2192-2195 http://purl.obolibrary.org/obo/CLO_0002941 denotes EPI
T18 2334-2340 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T19 2353-2354 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T20 2729-2734 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T21 2729-2734 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T22 2729-2734 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T23 2729-2734 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T24 2735-2741 http://www.ebi.ac.uk/efo/EFO_0000825 denotes valves
T25 2787-2789 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T26 3011-3015 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T27 3629-3630 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T28 4154-4158 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arms
T29 4426-4437 http://purl.obolibrary.org/obo/BFO_0000030 denotes Objectively
T30 4461-4469 http://purl.obolibrary.org/obo/UBERON_0001637 denotes arterial
T31 4461-4469 http://www.ebi.ac.uk/efo/EFO_0000814 denotes arterial
T32 4497-4501 http://purl.obolibrary.org/obo/CLO_0009316 denotes TE]4
T33 4540-4546 http://purl.obolibrary.org/obo/UBERON_0001005 denotes Airway
T34 4865-4866 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T35 4893-4894 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T36 5051-5062 http://purl.obolibrary.org/obo/BFO_0000030 denotes Objectively
T37 5086-5094 http://purl.obolibrary.org/obo/UBERON_0001637 denotes arterial
T38 5086-5094 http://www.ebi.ac.uk/efo/EFO_0000814 denotes arterial
T39 5122-5126 http://purl.obolibrary.org/obo/CLO_0009316 denotes TE]4
T40 5165-5171 http://purl.obolibrary.org/obo/UBERON_0001005 denotes Airway
T41 5472-5478 http://purl.obolibrary.org/obo/UBERON_0001969 denotes Plasma
T42 5554-5560 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T43 5819-5820 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T44 5843-5844 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T45 6080-6095 http://purl.obolibrary.org/obo/CL_0000232 denotes red blood cells
T46 6231-6234 http://www.ebi.ac.uk/efo/EFO_0000827 denotes eye
T47 6242-6243 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T48 6419-6420 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T49 6661-6662 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T50 6685-6686 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T51 6984-6985 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T52 7453-7454 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T53 7573-7574 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T54 7597-7598 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T55 7653-7654 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T56 7655-7658 http://purl.obolibrary.org/obo/CLO_0053733 denotes 1:1
T57 7717-7718 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T58 8172-8177 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T59 8651-8653 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T60 8691-8697 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tailed
T61 8703-8704 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T62 8980-8985 http://purl.obolibrary.org/obo/CLO_0001040 denotes 11/05
T63 9358-9361 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T64 9401-9402 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 98-105 Chemical denotes Heparin http://purl.obolibrary.org/obo/CHEBI_28304
T2 243-245 Chemical denotes HD http://purl.obolibrary.org/obo/CHEBI_73925
T3 355-362 Chemical denotes Heparin http://purl.obolibrary.org/obo/CHEBI_28304
T4 376-386 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T5 455-465 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T6 760-763 Chemical denotes AMI http://purl.obolibrary.org/obo/CHEBI_65009
T7 837-839 Chemical denotes TE http://purl.obolibrary.org/obo/CHEBI_74857
T8 1002-1008 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T9 1215-1220 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T10 1231-1236 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T11 1722-1728 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T12 2196-2206 Chemical denotes Creatinine http://purl.obolibrary.org/obo/CHEBI_16737
T13 2283-2290 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T14 2537-2547 Chemical denotes ophthalmic http://purl.obolibrary.org/obo/CHEBI_66981
T15 2621-2634 Chemical denotes anticoagulant http://purl.obolibrary.org/obo/CHEBI_50249
T16 2836-2848 Chemical denotes fondaparinux http://purl.obolibrary.org/obo/CHEBI_61033
T17 2868-2875 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T18 3295-3300 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T19 3322-3332 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T20 3468-3473 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T21 3495-3505 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T22 3738-3747 Chemical denotes vitamin K http://purl.obolibrary.org/obo/CHEBI_28384
T23 3738-3745 Chemical denotes vitamin http://purl.obolibrary.org/obo/CHEBI_33229
T24 3753-3767 Chemical denotes anticoagulants http://purl.obolibrary.org/obo/CHEBI_50249
T25 3784-3794 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T26 3883-3893 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T27 4064-4069 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T28 4104-4109 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T29 4420-4423 Chemical denotes AMI http://purl.obolibrary.org/obo/CHEBI_65009
T30 4497-4499 Chemical denotes TE http://purl.obolibrary.org/obo/CHEBI_74857
T31 4655-4661 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T32 5045-5048 Chemical denotes AMI http://purl.obolibrary.org/obo/CHEBI_65009
T33 5122-5124 Chemical denotes TE http://purl.obolibrary.org/obo/CHEBI_74857
T34 5280-5286 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T35 5549-5551 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T37 6009-6020 Chemical denotes haemoglobin http://purl.obolibrary.org/obo/CHEBI_35143
T38 7461-7465 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T39 8172-8177 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T40 8270-8275 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T41 8577-8582 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T42 8626-8631 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T43 8674-8679 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T44 8777-8782 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T45 8933-8940 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T46 9384-9390 Chemical denotes Letter http://purl.obolibrary.org/obo/CHEBI_6446

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 2169-2173 http://purl.obolibrary.org/obo/GO_0005006 denotes eGFR
T2 2238-2254 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-289 Sentence denotes Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
T2 290-301 Sentence denotes OBJECTIVES:
T3 302-721 Sentence denotes To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients with COVID19 not requiring Invasive Mechanical Ventilation [IMV], are: a)more effective in preventing clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:
T4 722-1160 Sentence denotes 1.Death2.Acute Myocardial Infarction [AMI]3.Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]4.Need of either: a.Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) orb.IMV in patients who at randomisation were receiving standard oxygen therapy5.IMV in patients who at randomisation were receiving non-invasive mechanical ventilationb)Similar in terms of major bleeding risk TRIAL DESIGN:
T5 1161-1278 Sentence denotes Multicentre, randomised controlled, superiority, open label, parallel group, two arms (1:1 ratio), in-hospital study.
T6 1279-1292 Sentence denotes PARTICIPANTS:
T7 1293-1446 Sentence denotes Inpatients will be recruited from 7 Italian Academic and non-Academic Internal Medicine Units, 2 Infectious Disease Units and 1 Respiratory Disease Unit.
T8 1447-1481 Sentence denotes INCLUSION CRITERIA (ALL REQUIRED):
T9 1482-1484 Sentence denotes 1.
T10 1485-1511 Sentence denotes Age > 18 and < 80 years 2.
T11 1512-1591 Sentence denotes Positive SARS-CoV-2 diagnostic (on pharyngeal swab of deep airways material) 3.
T12 1592-1790 Sentence denotes Severe pneumonia defined by the presence of at least one of the following criteria: a.Respiratory Rate ≥25 breaths /minb.Arterial oxygen saturation≤93% at rest on ambient airc.PaO2/FiO2 ≤300 mmHg 4.
T13 1791-1979 Sentence denotes Coagulopathy, defined by the presence of at least one of the following criteria: a.D-dimer >4 times the upper level of normal reference rangeb.Sepsis-Induced Coagulopathy (SIC) score >4 5.
T14 1980-2014 Sentence denotes No need of IMV EXCLUSION CRITERIA:
T15 2015-2017 Sentence denotes 1.
T16 2018-2042 Sentence denotes Age <18 and >80 years 2.
T17 2043-2049 Sentence denotes IMV 3.
T18 2050-2099 Sentence denotes Thrombocytopenia (platelet count < 80.000 mm3) 4.
T19 2100-2143 Sentence denotes Coagulopathy: INR >1.5, aPTT ratio > 1.4 5.
T20 2144-2231 Sentence denotes Impaired renal function (eGFR calculated by CKD-EPI Creatinine equation < 30 ml/min) 6.
T21 2232-2271 Sentence denotes Known hypersensitivity to enoxaparin 7.
T22 2272-2318 Sentence denotes History of heparin induced thrombocytopenia 8.
T23 2319-2608 Sentence denotes Presence of an active bleeding or a pathology susceptible of bleeding in presence of anticoagulation (e.g. recent haemorrhagic stroke, peptic ulcer, malignant cancer at high risk of haemorrhage, recent neurosurgery or ophthalmic surgery, vascular aneurysms, arteriovenous malformations) 9.
T24 2609-2746 Sentence denotes Concomitant anticoagulant treatment for other indications (e.g. atrial fibrillation, venous thromboembolism, prosthetic heart valves) 10.
T25 2747-2790 Sentence denotes Concomitant double antiplatelet therapy 11.
T26 2791-2961 Sentence denotes Administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization; prophylactic doses are allowed 12.
T27 2962-3019 Sentence denotes Pregnancy or breastfeeding or positive pregnancy test 13.
T28 3020-3178 Sentence denotes Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing medical condition) 14.
T29 3179-3246 Sentence denotes Lack or withdrawal of informed consent INTERVENTION AND COMPARATOR:
T30 3247-3413 Sentence denotes Control Group (Low-Dose LMWH): patients in this group will be administered Enoxaparin (Inhixa®) at standard prophylactic dose (i.e., 4000 UI subcutaneously once day).
T31 3414-3587 Sentence denotes Intervention Group (High-Dose LMWH): patients in this group will be administered Enoxaparin (Inhixa®) at dose of 70 IU/kg every 12 hours, as reported in the following table.
T32 3588-3993 Sentence denotes This dose is commonly used in Italy when a bridging strategy is required for the management of surgery or invasive procedures in patients taking anti-vitamin K oral anticoagulants Body Weight (kg)Enoxaparin dose every 12 hours (IU)<50200050-69400070-89600090-1108000>11010000 The treatment with Enoxaparin will be initiated soon after randomization (maximum allowed starting time 12h after randomization).
T33 3994-4110 Sentence denotes The treatment will be administered every 12 hours in the intervention group and every 24 hours in the control group.
T34 4111-4229 Sentence denotes Treatments will be administered in the two arms until hospital discharge or the primary outcomes detailed below occur.
T35 4230-4244 Sentence denotes MAIN OUTCOMES:
T36 4245-4271 Sentence denotes Primary Efficacy Endpoint:
T37 4272-4381 Sentence denotes Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:
T38 4382-4825 Sentence denotes 1.Death2.Acute Myocardial Infarction [AMI]3.Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]4.Need of either: a.Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) orb.IMV in patients who at randomisation were in standard oxygen therapy by delivery interfaces5.Need for IMV, in patients who at randomisation were in Cpap or NIV Time to the occurrence of each of these events will be recorded.
T39 4826-4913 Sentence denotes Clinical worsening will be analysed as a binary outcome as well as a time-to-event one.
T40 4914-4943 Sentence denotes Secondary Efficacy Endpoints:
T41 4944-5589 Sentence denotes Any of the following events occurring within the hospital stay 1.Death2.Acute Myocardial Infarction [AMI]3.Objectively confirmed, symptomatic arterial or venous thromboembolism [TE]4.Need of either: a.Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) orb.IMV in patients who at randomisation were in standard oxygen therapy by delivery interfaces5.Need for IMV in patients who at randomisation were in Cpap or NIV6.Improvement of laboratory parameters of disease severity, including: o D-dimer levelo Plasma fibrinogen levelso Mean Platelet Volumeo Lymphocyte/Neutrophil ratioo IL-6 plasma levels MORTALITY AT 30 DAYS:
T42 5590-5712 Sentence denotes Information about patients' status will be sought in those who are discharged before 30 days on Day 30 from randomisation.
T43 5713-5777 Sentence denotes Time to the occurrence of each of these events will be recorded.
T44 5778-5863 Sentence denotes Each of these events will be analysed as a binary outcome and as a time-to-event one.
T45 5864-5888 Sentence denotes Primary safety endpoint:
T46 5889-5996 Sentence denotes Major bleeding, defined as an acute clinically overt bleeding associated with one or more of the following:
T47 5997-6619 Sentence denotes Decrease in haemoglobin of 2 g/dl or more;Transfusion of 2 or more units of packed red blood cells;Bleeding that occurs in at least one of the following critical sites [intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];Bleeding that is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death);Bleeding that necessitates surgical intervention Time to the occurrence of each of these events will be recorded.
T48 6620-6705 Sentence denotes Each of these events will be analysed as a binary outcome and as a time-to-event one.
T49 6706-6732 Sentence denotes Secondary safety endpoint:
T50 6733-6877 Sentence denotes Clinically Relevant non-major bleeding, defined as an acute clinically overt bleeding that does not meet the criteria for major and consists of:
T51 6878-7466 Sentence denotes 1.Any bleeding compromising hemodynamic2.Spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause3.Intramuscular hematoma documented by ultrasonography4.Epistaxis or gingival bleeding requiring tamponade or other medical intervention5.Bleeding from venipuncture for >5 minutes6.Haematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures7.Haemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention8.Any other bleeding requiring temporary cessation of a study drug.
T52 7467-7531 Sentence denotes Time to the occurrence of each of these events will be recorded.
T53 7532-7617 Sentence denotes Each of these events will be analysed as a binary outcome and as a time-to-event one.
T54 7618-7632 Sentence denotes RANDOMISATION:
T55 7633-7863 Sentence denotes Randomisation (with a 1:1 randomisation ratio) will be centrally performed by using a secure, web-based system, which will be developed by the Methodological and Statistical Unit at the Azienda Ospedaliero-Universitaria of Modena.
T56 7864-7902 Sentence denotes Randomisation stratified by 4 factors:
T57 7903-8057 Sentence denotes 1) Gender (M/F); 2) Age (<75/≥75 years); 3) BMI (<30/≥30); 4) Comorbidities (0-1/>2) with random variable block sizes will be generated by STATA software.
T58 8058-8121 Sentence denotes The web-based system will guarantee the allocation concealment.
T59 8122-8276 Sentence denotes Blinding (masking) The study is conceived as open-label: patients and all health-care personnel involved in the study will be aware of the assigned group.
T60 8277-8316 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T61 8317-8478 Sentence denotes The target sample size is based on the hypothesis that LMWH administered at high doses versus low doses will significantly reduce the risk of clinical worsening.
T62 8479-8661 Sentence denotes The overall sample size in this study is expected to be 300 with 150 in the Low-Dose LMWH control group and 150 in the High-Dose LMWH intervention group, recruited over 10-11 months.
T63 8662-8941 Sentence denotes Assuming an alpha of 5% (two tailed) and a percentage of patients who experience clinical worsening in the control group being between 25% and 30%, the study will have 80% power to detect at least 50% relative reduction in the risk of death between low and high doses of heparin.
T64 8942-8955 Sentence denotes TRIAL STATUS:
T65 8956-8991 Sentence denotes Protocol version 1.2 of 11/05/2020.
T66 8992-9021 Sentence denotes Recruitment start (expected):
T67 9022-9063 Sentence denotes 08/06/2020 Recruitment finish (expected):
T68 9064-9271 Sentence denotes 30/04/2021 Trial registration EudraCT 2020-001972-13, registered on April 17th, 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T69 9272-9452 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 160-169 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T2 174-186 Phenotype denotes coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T3 737-758 Phenotype denotes Myocardial Infarction http://purl.obolibrary.org/obo/HP_0001658
T4 820-835 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T5 1599-1608 Phenotype denotes pneumonia http://purl.obolibrary.org/obo/HP_0002090
T6 1791-1803 Phenotype denotes Coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T7 1949-1961 Phenotype denotes Coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T8 2050-2066 Phenotype denotes Thrombocytopenia http://purl.obolibrary.org/obo/HP_0001873
T9 2100-2112 Phenotype denotes Coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T10 2238-2254 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T11 2283-2315 Phenotype denotes heparin induced thrombocytopenia http://purl.obolibrary.org/obo/HP_0011874
T12 2446-2452 Phenotype denotes stroke http://purl.obolibrary.org/obo/HP_0001297
T13 2454-2466 Phenotype denotes peptic ulcer http://purl.obolibrary.org/obo/HP_0004398
T14 2478-2484 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 2566-2575 Phenotype denotes aneurysms http://purl.obolibrary.org/obo/HP_0002617
T16 2577-2604 Phenotype denotes arteriovenous malformations http://purl.obolibrary.org/obo/HP_0100026
T17 2673-2692 Phenotype denotes atrial fibrillation http://purl.obolibrary.org/obo/HP_0005110
T18 2701-2716 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T19 4397-4418 Phenotype denotes Myocardial Infarction http://purl.obolibrary.org/obo/HP_0001658
T20 4480-4495 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T21 5022-5043 Phenotype denotes Myocardial Infarction http://purl.obolibrary.org/obo/HP_0001658
T22 5105-5120 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T23 6919-6939 Phenotype denotes Spontaneous hematoma http://purl.obolibrary.org/obo/HP_0007420
T24 7003-7025 Phenotype denotes Intramuscular hematoma http://purl.obolibrary.org/obo/HP_0012233
T25 7057-7066 Phenotype denotes Epistaxis http://purl.obolibrary.org/obo/HP_0000421
T26 7070-7087 Phenotype denotes gingival bleeding http://purl.obolibrary.org/obo/HP_0000225
T27 7294-7305 Phenotype denotes Haemoptysis http://purl.obolibrary.org/obo/HP_0002105
T28 7307-7318 Phenotype denotes hematemesis http://purl.obolibrary.org/obo/HP_0002248
T29 7334-7349 Phenotype denotes rectal bleeding http://purl.obolibrary.org/obo/HP_0002573